Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Non-Current Debt came in at $37.3 billion in Q2 2026, down 4.82% year-over-year from $39.2 billion in Q2 2025, and little changed quarter-over-quarter from $37.5 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Non-Current Debt across 18 years of filings, most recently posting $37.3 billion for Q2 2026.
- In Q2 2026, Non-Current Debt fell 4.82% year-over-year to $37.3 billion; the TTM figure through Jun 2026 stood at $37.3 billion (down 4.82% YoY), while the FY2025 annual figure was $39.4 billion, up 21.72% from the prior year.
- Non-Current Debt came in at $37.3 billion for Q2 2026 at Johnson & Johnson, roughly flat from $37.5 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $39.4 billion in Q4 2025 to a low of $25.1 billion in Q1 2024.
- Average Non-Current Debt over 5 years is $32.6 billion, with a median of $32.1 billion recorded in 2022.
- Year-over-year, Non-Current Debt slipped 28.19% in 2024 and surged 52.92% in 2025.
- Over 5 years, Non-Current Debt stood at $27.6 billion in 2022, then retreated by 0.92% to $27.4 billion in 2023, then increased by 18.46% to $32.4 billion in 2024, then increased by 21.72% to $39.4 billion in 2025, then slipped by 5.31% to $37.3 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $37.3 billion in Q2 2026, $37.5 billion in Q1 2026, and $39.4 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.39 Bn | 620.63 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 445.66 Bn | 439.09 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 357.45 Bn | 350.31 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 267.58 Bn | 259.89 Bn | 11.24 Bn | - |
| 5 | Pfizer | 156.75 Bn | 145.05 Bn | 10.94 Bn | 60.50 Bn |
| 6 | Sanofi | 52.14 Bn | 44.75 Bn | 10.79 Bn | 17.02 Bn |
| 7 | Revolution Medicines | 42.91 Bn | 42.91 Bn | - | - |
| 8 | Incyte | 24.62 Bn | 20.08 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.28 Bn | 18.62 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.81 Bn | 15.42 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 37.34 Bn |
| Mar 29, 2026 | 37.53 Bn |
| Dec 28, 2025 | 39.44 Bn |
| Sep 28, 2025 | 39.41 Bn |
| Jun 29, 2025 | 39.24 Bn |
| Mar 30, 2025 | 38.36 Bn |
| Dec 29, 2024 | 32.40 Bn |
| Sep 29, 2024 | 31.29 Bn |
| Jun 30, 2024 | 31.64 Bn |
| Mar 31, 2024 | 25.08 Bn |
| Dec 31, 2023 | 27.35 Bn |
| Oct 1, 2023 | 26.05 Bn |
| Jul 2, 2023 | 33.90 Bn |
| Apr 2, 2023 | 34.93 Bn |
| Jan 1, 2023 | 28.44 Bn |
| Oct 2, 2022 | 27.60 Bn |
| Jul 3, 2022 | 28.29 Bn |
| Apr 3, 2022 | 28.85 Bn |
| Jan 2, 2022 | 32.12 Bn |
| Oct 3, 2021 | 30.13 Bn |